Skip to main content
. Author manuscript; available in PMC: 2020 Sep 30.
Published in final edited form as: Vaccine. 2019 Sep 5;37(42):6208–6220. doi: 10.1016/j.vaccine.2019.08.030

Figure 5. Dose-dependent antibody responses of a TLR7/8-agonist-conjugated nanoparticle.

Figure 5.

HA-NP-3M012 immunogenicity was tested in mice at four doses: 0.1 μg, 0.5 μg, 2.5 μg, and 12.5 μg. Admixture controls and unconjugated nanoparticle were included for comparison. Serum neutralization was measured in the NC99 lentivirus reporter assay (left) and NC99 HAI assay (right). Arrows highlight the 2.5 μg dose, wherein the HA-NP-3M012 conjugate induced similar antibody titers to HA-NP + 3M012, despite containing over 5000-fold less 3M012 adjuvant. Mean ± SEM is graphed.